|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Factor** | **All SPVL****(n = 603)** | **Strict SPVL****(n = 240)** | **Abbott****(n = 31)** | **Roche1.5****(n = 572)** | **WR****(n = 299)** | **JH****(n = 129)** | **RHSP****(n = 175)** | **Male****(n = 268)** | **Female****(n = 335)** | **Subtype A** **(n = 94)** | **Subtype D** **(n = 285)** | **Other /unknown subtype** **(n = 224)** |
| John Hopkins | 0 | 0 | - | 0 | - | - | - | 0 | 0 | 0 | 0 | 0 |
| RHSP | 0.154 | 0.551 \*\* | - | 0.147 | - | - | - | 0.363 \* | -0.072 | -0.266 | 0.204 | 0.208 |
| Walter Reed | 0 | 0.287 ' | - | 0 | - | - | - | 0.108 | -0.146 | 0.085 | 0.012 | -0.22 |
| Abbott | 0 | 0 | - | - | - | - | 0 | 0 | 0 | - | 0 | 0 |
| Roche 1.5 | -0.189 | 1.048 \* | - | - | - | - | -0.136 | -0.081 | -0.101 | - | 0.094 | -0.534 \* |
| Not RCCS visit | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| **RCCS visit** | **-0.37 \*\*** | -0.268 | -0.112 | -0.368 \*\* | - | - | -0.444 \*\* | -0.49 \*\* | -0.132 | 0.271 | -0.264 | -0.738 \*\*\* |
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 0 |
| **Male** | **0.265 \*\*\*** | 0.404 \*\*\* | -0.108 | 0.273 \*\*\* | 0.277 \*\* | 0.16 | 0.375 \*\* | - | - | 0.321 \* | 0.148 | 0.378 \*\* |
| Circumcised | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Not Circumcised | - | - | - | - | - | - | - | -0.036 | - | - | - | - |
| **Age** | **0.008 \*** | -0.004 | 0 | 0.008 \* | 0.01 ' | 0.011 | 0.004 | 0.014 \* | 0.004 | 0.023 \* | 0.012 \* | -0.003 |
| **Date seroconversion** | **-0.033 \*\*** | -0.039 ' | -0.096 ' | -0.032 \* | 0 | -0.07 \* | -0.027 | -0.04 \* | -0.022 | -0.048 ' | -0.026 | -0.038 ' |
| Subtype A | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Subtype C | -0.447 | 0.284 | - | -0.448 | -0.318 | -0.874 | -0.447 | -0.606 | -0.399 | - | - | - |
| **Subtype D** | **0.213 \*** | 0.271 ' | 0 | 0.216 \* | 0.184 ' | 0.121 | 0.371 ' | 0.103 | 0.296 \* | - | - | - |
| Recombinant | 0.092 | -0.003 | 1.855 \* | 0.078 | 0.094 | 0.291 | -0.024 | 0.153 | 0.038 | - | - | - |
| Dual infections | -0.236 | -0.214 | - | -0.233 | -0.267 | -1.844 \* | 0.284 | -0.467 | -0.144 | - | - | - |

**Figure 2–source data 1. Data file for figure 2**. Summary of adjusted effects for the linear model explaining SPVL as a function of epidemiological covariates and date of seroconversion. The linear models included all the covariates listed. Effects significant in the whole dataset are in bold ‘ p < 0.1, \* p < 0.05, \*\* p < 0.01, \*\*\* p<0.001.